Navigation Links
Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease. The clinical study was carried out in collaboration with the Alzheimer's Disease Cooperative Study (ADCS) based at the University of California San Diego (UCSD) and funded by a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).  

Forty-nine (49) patients with mild to moderate Alzheimer's disease were treated with CERE-110 at 10 clinical sites throughout the U.S. Approximately half of the patients received CERE-110 while the other half received an appropriate sham (placebo) surgery control treatment. Patients will be followed for a minimum of two years with respect to safety, brain imaging, as well as measures of cognitive function and quality of life. Standard tests used in Alzheimer's clinical trials.

"We are very excited that enrollment in the first blinded study of NGF gene therapy for Alzheimer's disease is now completed and appreciate the courage of all of the patients and their family members that enrolled in this very important study. We also appreciate the efforts of the ADCS and the National Institute on Aging for carrying out and supporting the operational aspects of this study" stated Jeffrey M. Ostrove , Ph.D., president and chief executive officer of Ceregene, Inc., the developer of CERE-110. Dr. Ostrove added "In addition to CERE-110 for Alzheimer's disease, we have also completed enrollment in two controlled Phase 2 clinical trials of CERE-120 for Parkinson's disease. At this time, we would like to recognize the leadership role of Raymond T. Bartus , Ph.D., our chief scientific officer who led the development efforts for both of these potential products for the treatment of our most common neurodegenerative disorders".

"We were very pleased to be involved in evaluating CERE-110. We believe CERE-110 may prove to be an effective therapy for Alzheimer's disease," stated Paul Aisen , M.D., Project Director of the Phase Two trial and director of the Alzheimer's Disease Cooperative Study at University of California San Diego, a preeminent research consortium for testing new treatments for Alzheimer's disease. "If the results prove positive, which is our hope, this therapy could help the over five million people in the U.S. currently living with Alzheimer's disease in need of more effective treatment options." 

About CERE-110
CERE-110 is composed of an adeno-associated viral (AAV) vector carrying the gene for NGF, a naturally occurring protein that maintains survival of nerve cells in the brain. CERE-110 is surgically injected into the Nucleus Basalis of Meynert (NBM), a brain region where cholinergic cell degeneration occurs in Alzheimer's disease. The cholinergic system is important in memory and cognitive function, and a restoration in the function of this system may improve memory in individuals with Alzheimer's disease. Delivery of NGF using an AAV vector should have the potential to induce sustained expression of NGF, resulting in long-lasting restoration of the function.

About Alzheimer's Disease
Alzheimer's disease is a progressive disorder of the brain that gradually affects one's memory and ability to learn, reason, communicate and carry out daily activities. There are now more than five million people in the United States living with Alzheimer's disease, and there is currently no cure.

About Ceregene
Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery.  Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease.  Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Hamilton BioVentures, Investor Growth Capital, California Technology Partners and BioSante Pharmaceuticals (Nasdaq: BPAX).


'/>"/>
SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
2. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
3. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
4. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
5. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
6. Parkinsons Disease: World Drug Market 2013-2023
7. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
8. Adventrx To Develop ANX-188 For Complications Of Arterial Disease
9. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
10. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
11. Shire Supports Rare Disease Day 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded ... to confront and deal with these stressors is to adopt a more healthful diet, ... for you. Risa Groux, a certified Holistic Nutritionist and the creator of the Newport ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Reltok ... devices and products for the head and neck/ear, nose and throat specialty, has added ... , The KOTLER NASAL AIRWAY™ is a newly patented safety device secured ...
Breaking Medicine News(10 mins):